

ClÃ©mence Martin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9281365/publications.pdf>

Version: 2024-02-01

27
papers

731
citations

686830

13
h-index

552369

26
g-index

28
all docs

28
docs citations

28
times ranked

809
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 64-73.	2.5	139
2	Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 188-197.	2.5	95
3	Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!. Journal of Cystic Fibrosis, 2016, 15, 204-212.	0.3	76
4	Aspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapy. Infection and Drug Resistance, 2016, Volume 9, 229-238.	1.1	53
5	Prognostic value of six minute walk test in cystic fibrosis adults. Respiratory Medicine, 2013, 107, 1881-1887.	1.3	51
6	Increased IgA Expression in Lung Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 592-602.	2.5	40
7	Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. European Respiratory Journal, 2017, 49, 1601873.	3.1	38
8	Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 489-496.	0.3	38
9	Major Decrease in Lung Transplantation for Patients with Cystic Fibrosis in France. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 584-586.	2.5	26
10	Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. Journal of Cystic Fibrosis, 2021, 20, 220-227.	0.3	24
11	Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis. European Respiratory Journal, 2021, , 2101344.	3.1	19
12	Dysfunctional lung anatomy and small airways degeneration in COPD. International Journal of COPD, 2013, 8, 7.	0.9	17
13	CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Cells, 2022, 11, 1769.	1.8	17
14	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000653.	3.1	16
15	Impact of panelists's™ experience on script concordance test scores of medical students. BMC Medical Education, 2020, 20, 313.	1.0	15
16	Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected Lungs. Methods in Molecular Biology, 2018, 1845, 223-239.	0.4	10
17	Reply to Kuek <i>et Al.</i>: Optimism with Caution: Elexacaftor-Tezacaftor-Ivacaftor in Patients with Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 372-374.	2.5	10
18	Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test. European Respiratory Journal, 2022, 60, 2200209.	3.1	8

#	ARTICLE	IF	CITATIONS
19	Safety of Omalizumab During Pregnancy and Breast-Feeding With Assessment of Placental Transfer: A Case Report. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 515.	1.1	7
20	Do Cough and Sputum Production Predict COPD Exacerbations?. <i>Chest</i> , 2019, 156, 641-642.	0.4	6
21	Effective control of <i>Staphylococcus aureus</i> lung infection despite tertiary lymphoid structure disorganisation. <i>European Respiratory Journal</i> , 2021, 57, 2000768.	3.1	6
22	Carriers of a single <i>CFTR</i> mutation are asymptomatic: an evolving dogma?. <i>European Respiratory Journal</i> , 2020, 56, 2002645.	3.1	5
23	Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis. <i>Journal of Clinical Pathology</i> , 2018, 71, 752-753.	1.0	4
24	Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores. <i>Radiology: Cardiothoracic Imaging</i> , 2020, 2, e200022.	0.9	4
25	Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries. <i>European Respiratory Journal</i> , 2021, 58, 2101487.	3.1	2
26	Cystic Fibrosis in 2021: "The Times They Are A-Changin". <i>Archivos De Bronconeumologia</i> , 2022, 58, 536-538.	0.4	1
27	Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021. <i>Respiratory Medicine and Research</i> , 2022, 81, 100889.	0.4	0